- Home
- EDIT vs DMAC Comparison
EDIT vs DMAC Comparison
Compare EDIT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- DMAC
- Stock Information
- Founded
- EDIT 2013
- DMAC 2000
- Country
- EDIT United States
- DMAC United States
- Employees
- EDIT N/A
- DMAC N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- DMAC Health Care
- Exchange
- EDIT Nasdaq
- DMAC Nasdaq
- Market Cap
- EDIT 269.8M
- DMAC 321.5M
- IPO Year
- EDIT 2016
- DMAC N/A
- Fundamental
- Price
- EDIT $2.40
- DMAC $8.91
- Analyst Decision
- EDIT Buy
- DMAC Strong Buy
- Analyst Count
- EDIT 10
- DMAC 4
- Target Price
- EDIT $4.13
- DMAC $15.50
- AVG Volume (30 Days)
- EDIT 2.0M
- DMAC 477.0K
- Earning Date
- EDIT 11-10-2025
- DMAC 11-12-2025
- Dividend Yield
- EDIT N/A
- DMAC N/A
- EPS Growth
- EDIT N/A
- DMAC N/A
- EPS
- EDIT N/A
- DMAC N/A
- Revenue
- EDIT $46,383,000.00
- DMAC N/A
- Revenue This Year
- EDIT N/A
- DMAC N/A
- Revenue Next Year
- EDIT N/A
- DMAC N/A
- P/E Ratio
- EDIT N/A
- DMAC N/A
- Revenue Growth
- EDIT N/A
- DMAC N/A
- 52 Week Low
- EDIT $0.91
- DMAC $3.19
- 52 Week High
- EDIT $4.54
- DMAC $9.15
- Technical
- Relative Strength Index (RSI)
- EDIT 34.46
- DMAC 73.52
- Support Level
- EDIT $2.30
- DMAC $7.06
- Resistance Level
- EDIT $2.55
- DMAC $6.47
- Average True Range (ATR)
- EDIT 0.20
- DMAC 0.64
- MACD
- EDIT -0.00
- DMAC 0.27
- Stochastic Oscillator
- EDIT 20.00
- DMAC 94.92
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.